Q3 FY22 Earnings Presentation

Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions ESG Appendix Neuroscience COVID-19 driven procedural slowdowns; share gains and strong product pipeline Cranial & Spinal Technologies Spine & Biologics ▲ HSD Growth driven by HSD gains in U.S. and Japan and LSD growth in Western Europe • Continued success of Catalyft™ next-generation expandable interbody device launch driving U.S. share gains • • Impact of COVID-19 and hospital staffing challenges on procedures in the U.S. and Western Europe affected the spine market Neurosurgery Flat Driven by LDD growth in CSF Management, Advanced Energy, and HSD growth in Midas Rex™ powered surgical instruments, offset by a difficult comparison from strong capital sales in Q3 FY21 Surgeons continued to adopt our leading ecosystem of enabling technologies for spine surgery Listen to our latest Investor Relations GM Call Series featuring Cranial & Spinal Technologies 30% Specialty Therapies Neuroscience 51% Cranial & Spinal Technologies Catalyft™ Expandable Interbody System 16 Q3 FY22 earnings presentation | February 22, 2022 Midas Rex™ MR8™ High-speed Drill System 19% Neuromodulation Medtronic

View entire presentation